Topline data also show that lorundrostat reduces albuminuria in hypertensive patients with CKD. Topline results from the phase 2 Explore-CKD trial show lorundrostat, an aldosterone synthase inhibitor, ...

Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN Trial ...

Source: Getty Images Beyond sodium restriction, managing micronutrient intakes is an important part of medical nutrition therapy to control high blood pressure. Blood pressure management is a ...

Childhood cancer survivors had an increased risk of chronic kidney disease and hypertension. Childhood cancer survivors had twofold and fourfold higher adjusted risks versus a hospitalized cohort and ...

For patients with type 1 diabetes (T1D), a positive test or hospitalization for COVID-19 increases the risk of developing hypertension, chronic kidney disease (CKD), and diabetic ketoacidosis (DKA).

Lorundrostat led to significant reductions in systolic blood pressure and UACR in CKD patients. Adverse events were low, with 3% discontinuing during lorundrostat vs. 2% on placebo. A new wave of ...

AASK [ 2] is a randomized trial that examined three treatments?metoprolol, amlodipine, and ramipril?as initial therapy in 1094 African Americans with hypertensive renal disease. To be included, ...

Mortality from hypertensive kidney disease in the U.S. has grown by 48%, according to an abstract presented Sept. 5 at the American Heart Association’s 2025 Hypertension Scientific Sessions.

Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function.This tool will be launched as ...